Paradoxical elevation of plasma dabigatran after reversal with idarucizumab in stroke thrombolysis

J Neurol. 2018 Oct;265(10):2451-2453. doi: 10.1007/s00415-018-9011-8. Epub 2018 Aug 16.

Authors

Satoshi Hosoki¹, Masahito Takagi², Hiroshi Yamagami³, Daisuke Ando¹, Kazunori Toyoda¹, Masatoshi Koga¹

Affiliations

¹ Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka, 565-8565, Japan.
² Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka, 565-8565, Japan. tamasa@ncvc.go.jp.
³ Division of Stroke Care Unit, National Cerebral and Cardiovascular Center, Suita, Japan.

PMID: 30116941
DOI: 10.1007/s00415-018-9011-8

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / pharmacology*
Antithrombins / blood*
Dabigatran / blood*
Fibrinolytic Agents / administration & dosage
Fibrinolytic Agents / pharmacology*
Humans
Male
Stroke / drug therapy*
Tissue Plasminogen Activator / administration & dosage
Tissue Plasminogen Activator / pharmacology*

Substances

Antibodies, Monoclonal, Humanized
Antithrombins
Fibrinolytic Agents
idarucizumab
Tissue Plasminogen Activator
Dabigatran